RYR2 and catecholaminergic polymorphic ventricular tachycardia: Flecainide, which has demonstrated efficacy in catecholaminergic polymorphic ventricular tachycardia (CPVT) and ARVC, is thought to limit the outflow of calcium through the RyR2 channel.